ResMed Inc. (RMD) Hit a 52 Week High, Can the Run Continue?

ResMed (RMD) recently reached a new 52-week high of $268.65, significantly outperforming its sector with a 16.9% year-to-date gain, primarily attributed to a consistent track record of positive earnings surprises over the past four quarters. Despite trading at a premium valuation, with a 25.6x current fiscal year EPS estimate compared to the peer average of 19.1x, the company maintains a Zacks Rank #2 (Buy) due to favorable analyst revisions and projected earnings growth exceeding 10% for the current fiscal year, suggesting potential for continued upside.

Analysis

ResMed Inc. (RMD) has demonstrated significant market outperformance, reaching a new 52-week high of $268.65 after a 16.9% year-to-date gain, sharply contrasting with the -5.2% decline in the broader Zacks Medical sector. This momentum is underpinned by a consistent record of positive earnings surprises over the last four quarters and favorable forward guidance, with analysts expecting year-over-year EPS growth of 10.17% and revenue growth of 7.53% in the next fiscal year. These positive revisions have earned the stock a Zacks Rank of #2 (Buy) and strong Growth and Momentum scores of 'B'. However, this performance comes at a premium valuation. RMD currently trades at 25.6 times its current fiscal year EPS estimate and 29 times its trailing cash flow, substantially higher than the respective peer averages of 19.1X and 10.2X. This elevated valuation, reflected in a 'C' for Value Score and a PEG ratio of 1.67, presents a key risk for investors weighing the company's strong growth trajectory against its current price.

Key Decisions for Investors

• Investors with a growth mandate may find RMD attractive due to its strong momentum, consistent earnings beats, and double-digit forward EPS growth forecast, which support the current 'Buy' rating.
• Value-conscious investors should exercise caution, as the stock's valuation metrics, particularly its forward P/E and price-to-cash flow ratios, are significantly elevated compared to its industry peers, suggesting the stock may be fully priced.
• For those seeking alternative exposure in the medical products space, it may be prudent to evaluate peer Phibro Animal Health Corporation (PAHC), which the article highlights for its 'Strong Buy' rating, superior style scores, and more attractive valuation multiples.